=Ab s t r a c t = Iodinated contrast media (CM) can cause immediate and late reactions. We treated a patient with a recurrent generalized maculopapular rash and a fever that occurred within two days of exposure to iodinated CM, iopromide (Ultravist ® ), for chest computed tomography. We performed skin testing including prick tests, intradermal tests, and patch tests. Our findings indicated a late skin reaction to Ultravist®in addition to cross-reactions to other iodinated CM such as ioversol (Optiray 
hour but less than seven days following CM administration 1) . The late adverse reactions mainly manifest with, headaches, rashes, itching, limited urticaria, nausea, and dizziness. The most common type of late skin reaction is a generalized maculopapular exanthema (more than 50% of the cases), although there are other types of reactions such as pruritus, urticaria, angioedema, and less commonly, severe forms of erythema multiforme, vasculitis, Stevens-Johnson syndrome, and hypersensibility syndrome 1) . hypersensitivity Here in, we report a patient with a generalized maculopapular rash and a fever that occurred within two days, following the use of X-ray CM (Ultravist 
Ca s er e p o r t
A 4-year-old boy was admitted for the clinical evaluation and treatment of swelling and tenderness in the neck in addition to a fever. The symptoms developed two days prior to admission and were worsening. On presentation, the body temperature was 38.0°C with a pulse rate of 142 beats/minute, the respiratory rate was 30 breaths/minute and the blood pressure 90/60 mm/Hg. On physical examination, the patient had a rash, was warm and had tenderness and swelling from the lower chin to the upper anterior chest. The laboratory data were as follows: a total white blood cell count of 15,000/ µL that was neutrophil dominant (93.5%), hemoglobin (Hgb) of 12.7 g/dL and the C-reactive protein (CRP) was increased . However, the true frequency is difficult to determine due to variations in the patients studied and the methodologies used.
The reports on late reactions to CM commonly include symptoms such as headaches, skin rashes, itching, nausea, dizziness, urticaria, fever, arm pain, and gastrointestinal disturbances. The majority of late skin reactions to CM present as a mild to moderate generalized maculopapular exanthema that usually involves the trunk and proximal aspects of the upper and lower limbs although, as in our series, can present with facial and distal limb involvement 6) .
The pathophysiological mechanism of CM-Induced late reactions remains unclear 1) . However, most of late skin eruptions appear to be T-cell mediated allergic reactions. This is supported by the frequently of reported positive patch tests, delayed intradermal tests to the CM previously exposed to, the presence of dermal infiltrates of T cells in affected skin, positive skin test sites, the reappearance of the eruption after provocation testing, and the ability of CM to stimulate proliferation of peripheral T cells from patients with CMinduced skin eruptions 7) .
Skin tests are very important diagnostic tools in patients with late skin reactions to CM 1) . Three types of tests are commonly used: the skin prick test, the intradermal test and the patch test. The former two tests are used for the diagnosis of both IgE-mediated and T-cell mediated reactions, whereas the patch test is used to diagnose T-cell mediated reactions only. Patch tests with undiluted CM on the back and readings after two and three to four days, and intradermal tests with diluted CM and late readings after one to three days appear to be specific and useful in the clinical setting.
Both the patch test and intradermal test should be read after one week, if previously negative 8) .
To avoid a severe immediate anaphylactic reaction, a prick test with undiluted CM read after 15-20 min should be conducted before performing an intradermal test. However, the role of skin testing continues to be debated; some studies report a greater sensitivity with intradermal tests 6) , while others, report that the patch test is more frequently positive 9) .
In patients with late skin eruptions in response to CM, other organs may be involved 10) . Thus, during the acute phase of more severe reactions, laboratory tests such as liver and renal function tests as well as differential blood cell counts should be performed to evaluate for other systemic effects. However, currently there is no data available regarding the frequency of laboratory test abnormalities in these patients 7) .
Certain risk factors have been associated with the development of late skin reactions to CM. These include a history of previous reactions to CM, female gender, cardiac disease, diabetes mellitus, renal failure, and concomitant treatment with interleukin-2 or beta-blockers 7, 11, 12) . A seasonal variation in the incidence of late skin reactions has been described with 45% of the reactions occurring during the period from April to June in Finland 13) .
When late skin reactions to CM occur they usually develop within one to seven days with the majority occurring within the first three days 14) . Most reactions are self-limiting and resolve within seven days, with up to three-quarters resolving within three days 14) . The patient management is symptomatic and similar to the management of other drug-induced skin reactions 5) .
Patients with late skin reactions to CM are at risk for developing new eruptions if exposed again to the same CM, Therefore, this should be avoided by using a different class of CM. However, the frequency of cross-sensitivity to different CM is a problem 6) ; up to 75% of cases have crosssensitivity to other CM. Cross-sensitivity occurs among the ionic and nonionic, monomeric and dimeric agents. Therefore, change of CM is no guarantee against a repeat reaction 12)
. Therefore, avoidance of the causative agent is the safest course. Some have recommended premedication with oral corticosteroids and antihistamines as prophylaxis; however, there is no evidence to support the efficacy of these measures 12) . A novel pretreatment protocol was recently described by Romano et al. 15) . They reported the successful use of 
